Navigation Links
Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
Date:6/9/2009

- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations -

NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced a significant inhibition in the progression of structural joint damage compared with patients treated with methotrexate alone. These data will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark, along with additional studies that support the use of ACTEMRA as a long-term treatment option for patients with moderately to severely active RA.

In the one-year LITHE study, disease remission (DAS28(1) <2.6) was demonstrated in 30 percent and 47 percent of patients treated with ACTEMRA 4 mg/kg and 8 mg/kg, respectively, compared with 8 percent of patients treated with placebo plus methotrexate.

"Inhibiting RA from progressing further by achieving disease remission provides real-life benefits to patients, while at the same time helping them maintain day-to-day function," said Joel Kremer, M.D., lead investigator of the LITHE study and Director of Research at The Center for Rheumatology in Albany, New York. "The LITHE study also demonstrated the efficacy of ACTEMRA even in patients with a relatively long disease duration, which suggests that it may be an effective treatment option for many RA patients."

Additionally, the one-year LITHE study results showed that patients treated with ACTEMRA (4 mg/kg or 8 mg/kg) plus methotrexate experienced a significant inhibition in the progression of structural joint damage, as measured by
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
9. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
(Date:6/30/2015)... ... 2015 , ... The U.S. Women's National Soccer Team will face the Costa Rica Women's ... on Sunday, August 16th at Heinz Field in Pittsburgh at 1:30 p.m. local time. ... in Chattanooga, TN. , The USA WNT previously played at Heinz Field in Pittsburgh and ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion ... that fat transfer procedures had over breast implants when reconstructing breasts after a ... that “look and feel natural,” have increased sensation, and are less likely than ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... now the official ready-to-drink sponsor of two leading organizations dedicated to raising worldwide ... Required (SAR). , I AM ADAPTIVE™ is now the official charity of FitAID. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... NJ Top ... On May 13th, she hosted a CPR Course for members of the Bergen County ... can get updated on the latest CPR recommendations for Healthcare Providers. Life Support ...
(Date:6/30/2015)... ... June 30, 2015 , ... The Citizens Commission on ... (D-IL) for writing to the Department of Health and Human Services (HHS), requesting ... system, Universal Health Services (UHS).[1] CCHR is expanding its seven-year review of UHS ...
Breaking Medicine News(10 mins):Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:LifeAID Beverage Company Partners With The Adaptive Movement 2Health News:LifeAID Beverage Company Partners With The Adaptive Movement 3Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 2Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5
... and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that ... tablets has been submitted to the U.S. Food ... with hepatocellular carcinoma (HCC), the most common form of ... more than 50 countries for the treatment of advanced ...
... at the J. Craig Venter Institute (JCVI) today announced ... them to transform one type of bacteria into another ... ,The work, published online in the journal Science, by ... and techniques used to change one bacterial species, Mycoplasma ...
... similar effect to antidepressants on depression. Exercise stimulates new ... scientific reports, she has searched for the underlying biological ... of therapy for depression and has also compared it ... ,The experiment studies were conducted on rats. The results ...
... customers shisha water pipes to smoke tobacco are waging an ... comes into force in England on Sunday. ... are variously called, dozens of restaurants will lose their main ... activity disappear. ,"It's a disaster, we don't know ...
... withdrawn an application for regulatory approval for its anti-obesity drug ... of experts from the US Food and Drug Administration concluded ... rimonabant by the company, was unsafe and should not be ... towards submitting the rimonabant file to the FDA at a ...
... in a name, one might rhetorically ask. But Malaccan state ... bat virus after their region. And now the virus will ... Malaysian scientists announced last week they discovered a new virus ... humans. They called it the Melaka Virus, using the name ...
Cached Medicine News:Health News:Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 3Health News:Mealaka Virus Will Have a New Name 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: